<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03297125</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00000087</org_study_id>
    <nct_id>NCT03297125</nct_id>
  </id_info>
  <brief_title>Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI</brief_title>
  <official_title>Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective, nonrandomized controlled phase IV study is to compare
      standard and advanced MRI for their ability to predict response to Optune therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol Summary: Optune therapy is a newly approved treatment for patients with
      glioblastoma. This therapy demonstrated comparable outcomes for patients with recurrent GBM,
      in comparison to standard therapies, but better quality of life. More recently, in an interim
      analysis of 315 patients with GBM, adding TTFields to maintenance temozolomide chemotherapy
      significantly prolonged progression-free and overall survival. It also has demonstrated
      promise in other cancers such as pancreas, mesothelioma, ovarian and lung. However, in order
      to optimize the treatment regimen, and potentially predict which patients are most likely to
      respond, reliable ways of evaluation are necessary. Advanced perfusion and diffusion MRI
      methods have shown utility with other treatments such as bevacizumab. Preliminary data
      suggests the same might be true for the evaluation of Optune therapy. The team therefore
      proposes to determine the utility of these methods to predict response to Optune therapy. A
      successful result will have wide-ranging implications not only for the optimization of Optune
      treatment of brain cancer but also other cancers shown to benefit from this novel therapy.

      Objective: To compare standard and advanced MRI for their ability to predict response to
      Optune therapy. The team's approach will be to obtain both standard and advanced MRI in
      patients with newly diagnosed glioblastoma undergoing adjuvant chemotherapy plus Optune
      therapy. The ability of standard and advanced MRI to predict response will be assessed. The
      hypothesis is that perfusion and/or diffusion imaging metrics can be used to predict response
      to and elucidate mechanisms of action for Optune treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Device: NovoCure-TTF-200A
How TTFields works:
Adhesive bandages hold insulated ceramic discs (transducer arrays) that deliver electricity transformed into electromagnetic energy to the scalp. The battery operated-TTF device generates low intensity, intermediate frequency, alternating electrical fields to the brain. These electrical fields exert selective toxicity in proliferating cells thereby halting cell division and destroying the cancer cells.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In comparing the difference in the proportion of survival predicted by the two methods (standard versus advanced MRI), a McNemar test will be used.</measure>
    <time_frame>Two years</time_frame>
    <description>For 30 subjects enrolled in this study (over two years), assuming the proportion of discordant pairs is 0.30; the team will achieve 80% power to detect a difference between two paired proportions of 0.27 with a significance level of 0.05. Further, the team can give estimates of the positive predictive values of each method along with the 95% CI. If the difference between the two methods is smaller than what is assumed here, then the team will not be able to get a significant result with the provided sample size.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Using diffusion-weighted imaging (DWI), collect images at several different diffusion weightings and evaluate them by applying several different post-processing techniques.</measure>
    <time_frame>Two years</time_frame>
    <description>This information will provide specific micro-structural and cellular information about tumors.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Newly Diagnosed Glioblastoma</condition>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Imaging: Standard MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anticipated Results/Interpretation Standard anatomic imaging will prove not to be reliable for evaluation of progression free survival, but may show some ability to predict overall survival.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imaging: Advanced MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anticipated Results/Interpretation Advanced MRI methods will demonstrate the ability to predict response earlier than with standard MRI methods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NovoCure-TTF-200A</intervention_name>
    <description>Adhesive bandages hold insulated ceramic discs (transducer arrays) that deliver electricity transformed into electromagnetic energy to the scalp. The battery operated-TTF device generates low intensity, intermediate frequency, alternating electrical fields to the brain. These electrical fields exert selective toxicity in proliferating cells thereby halting cell division and destroying the cancer cells.</description>
    <arm_group_label>Imaging: Standard MRI</arm_group_label>
    <arm_group_label>Imaging: Advanced MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed glioblastoma (GBM), WHO grade IV.

        Exclusion Criteria:

          -  Optune compliance &lt; 75%; they would be excluded from the final analyses.

          -  History of craniectomy or significant skull defect (contraindication to Optune).

          -  Active implantable medical device (i.e. DBS, spinal cord stimulator, pacemaker,
             defibrillator, vagus nerve stimulator, programmable shunt).

          -  Karnofsky Performance Status (KPS) &lt; 60.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Connelly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical College of Wisconsin Clinical Cancer Center</last_name>
    <phone>414-805-8900</phone>
    <email>cccto@mcw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Froedtert Hospital &amp; Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Connelly, MD</last_name>
      <phone>414-805-5200</phone>
      <email>JConnelly@mcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Medical College of Wisconsin Cancer Center Clinical Trials Office</last_name>
      <phone>414-805-8900</phone>
      <email>cccto@mcw.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbal√Ω V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012 Sep;48(14):2192-202. doi: 10.1016/j.ejca.2012.04.011. Epub 2012 May 18.</citation>
    <PMID>22608262</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669.</citation>
    <PMID>26670971</PMID>
  </reference>
  <reference>
    <citation>Rivera, F., et al. PANOVA: A pilot study of TTFields concomitant with gemcitabine for front-line therapy of advanced pancreatic adenocarcinoma. in 2015 ASCO Annual Meeting. 2015. Chicago, IL.</citation>
  </reference>
  <reference>
    <citation>Grosso F, MƒÖdrzak J, Crin√≤ L, Chella A, Weinberg U, Ceresoli GL. 215TiP: STELLAR - A phase II trial of TTFields with chemotherapy for first line treatment of malignant mesothelioma. J Thorac Oncol. 2016 Apr;11(4 Suppl):S150. doi: 10.1016/S1556-0864(16)30322-7. Epub 2016 Apr 15.</citation>
    <PMID>27198350</PMID>
  </reference>
  <reference>
    <citation>Voloshin T, Munster M, Blatt R, Shteingauz A, Roberts PC, Schmelz EM, Giladi M, Schneiderman RS, Zeevi E, Porat Y, Bomzon Z, Urman N, Itzhaki A, Cahal S, Kirson ED, Weinberg U, Palti Y. Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo. Int J Cancer. 2016 Dec 15;139(12):2850-2858. doi: 10.1002/ijc.30406. Epub 2016 Sep 19.</citation>
    <PMID>27561100</PMID>
  </reference>
  <reference>
    <citation>Paulson ES, Prah DE, Schmainda KM. Spiral Perfusion Imaging With Consecutive Echoes (SPICE‚Ñ¢) for the Simultaneous Mapping of DSC- and DCE-MRI Parameters in Brain Tumor Patients: Theory and Initial Feasibility. Tomography. 2016 Dec;2(4):295-307. doi: 10.18383/j.tom.2016.00217.</citation>
    <PMID>28090589</PMID>
  </reference>
  <reference>
    <citation>Cohen, A.D., et al. IVIM and DSC metrics are heightened in rat C6 brain tumors. in 20th Annual Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM). 2012. Melbourne, Australia.</citation>
  </reference>
  <reference>
    <citation>Cohen AD, LaViolette PS, Prah M, Connelly J, Malkin MG, Rand SD, Mueller WM, Schmainda KM. Effects of perfusion on diffusion changes in human brain tumors. J Magn Reson Imaging. 2013 Oct;38(4):868-75. doi: 10.1002/jmri.24042. Epub 2013 Feb 6.</citation>
    <PMID>23389889</PMID>
  </reference>
  <reference>
    <citation>Farid N, Almeida-Freitas DB, White NS, McDonald CR, Muller KA, Vandenberg SR, Kesari S, Dale AM. Restriction-Spectrum Imaging of Bevacizumab-Related Necrosis in a Patient with GBM. Front Oncol. 2013 Sep 30;3:258. doi: 10.3389/fonc.2013.00258. eCollection 2013.</citation>
    <PMID>24137566</PMID>
  </reference>
  <reference>
    <citation>McDonald CR, Delfanti RL, Krishnan AP, Leyden KM, Hattangadi-Gluth JA, Seibert TM, Karunamuni R, Elbe P, Kuperman JM, Bartsch H, Piccioni DE, White NS, Dale AM, Farid N. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma. Neuro Oncol. 2016 Nov;18(11):1579-1590. Epub 2016 Apr 21.</citation>
    <PMID>27106406</PMID>
  </reference>
  <reference>
    <citation>White NS, Leergaard TB, D'Arceuil H, Bjaalie JG, Dale AM. Probing tissue microstructure with restriction spectrum imaging: Histological and theoretical validation. Hum Brain Mapp. 2013 Feb;34(2):327-46. doi: 10.1002/hbm.21454. Epub 2012 Jan 16.</citation>
    <PMID>23169482</PMID>
  </reference>
  <reference>
    <citation>Schmainda KM, Prah M, Connelly J, Rand SD, Hoffman RG, Mueller W, Malkin MG. Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro Oncol. 2014 Jun;16(6):880-8. doi: 10.1093/neuonc/not216. Epub 2014 Jan 15.</citation>
    <PMID>24431219</PMID>
  </reference>
  <reference>
    <citation>Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS, Bedekar DP, Schmainda KM. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging. 2010 Mar;31(3):538-48. doi: 10.1002/jmri.22068.</citation>
    <PMID>20187195</PMID>
  </reference>
  <reference>
    <citation>2005-2006 Primary brain tumors in the United States statistical report: 1998-2002 data collected., C.B.T.R.o.t.U. States, Editor. 2005</citation>
  </reference>
  <reference>
    <citation>Henson JW, Ulmer S, Harris GJ. Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol. 2008 Mar;29(3):419-24. doi: 10.3174/ajnr.A0963. Epub 2008 Feb 13. Review.</citation>
    <PMID>18272557</PMID>
  </reference>
  <reference>
    <citation>Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol. 2009 Dec;22(6):633-8. doi: 10.1097/WCO.0b013e328332363e. Review.</citation>
    <PMID>19770760</PMID>
  </reference>
  <reference>
    <citation>Schmainda KM, Rand SD, Joseph AM, Lund R, Ward BD, Pathak AP, Ulmer JL, Badruddoja MA, Krouwer HG. Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. AJNR Am J Neuroradiol. 2004 Oct;25(9):1524-32. Erratum in: AJNR Am J Neuroradiol. 2005 Mar;26(3):686. Baddrudoja, Michael A [corrected to Badruddoja, Michael A].</citation>
    <PMID>15502131</PMID>
  </reference>
  <reference>
    <citation>Paulson ES, Schmainda KM. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology. 2008 Nov;249(2):601-13. doi: 10.1148/radiol.2492071659. Epub 2008 Sep 9.</citation>
    <PMID>18780827</PMID>
  </reference>
  <reference>
    <citation>Schmainda KM, Zhang Z, Prah M, Snyder BS, Gilbert MR, Sorensen AG, Barboriak DP, Boxerman JL. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Neuro Oncol. 2015 Aug;17(8):1148-56. doi: 10.1093/neuonc/nou364. Epub 2015 Feb 2.</citation>
    <PMID>25646027</PMID>
  </reference>
  <reference>
    <citation>Bennett KM, Hyde JS, Rand SD, Bennett R, Krouwer HG, Rebro KJ, Schmainda KM. Intravoxel distribution of DWI decay rates reveals C6 glioma invasion in rat brain. Magn Reson Med. 2004 Nov;52(5):994-1004.</citation>
    <PMID>15508160</PMID>
  </reference>
  <reference>
    <citation>Ellingson BM, Cloughesy TF, Zaw T, Lai A, Nghiemphu PL, Harris R, Lalezari S, Wagle N, Naeini KM, Carrillo J, Liau LM, Pope WB. Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2012 Mar;14(3):333-43. doi: 10.1093/neuonc/nor220. Epub 2012 Jan 22.</citation>
    <PMID>22270220</PMID>
  </reference>
  <reference>
    <citation>Vymazal J, Wong ET. Response patterns of recurrent glioblastomas treated with tumor-treating fields. Semin Oncol. 2014 Oct;41 Suppl 6:S14-24. doi: 10.1053/j.seminoncol.2014.09.009. Epub 2014 Sep 16. Erratum in: Semin Oncol. 2015 Jun;42(3):e44-55.</citation>
    <PMID>25213870</PMID>
  </reference>
  <reference>
    <citation>Cohen AD, Schieke MC, Hohenwalter MD, Schmainda KM. The effect of low b-values on the intravoxel incoherent motion derived pseudodiffusion parameter in liver. Magn Reson Med. 2015 Jan;73(1):306-11. doi: 10.1002/mrm.25109. Epub 2014 Jan 29.</citation>
    <PMID>24478175</PMID>
  </reference>
  <reference>
    <citation>Bennett KM, Hyde JS, Schmainda KM. Water diffusion heterogeneity index in the human brain is insensitive to the orientation of applied magnetic field gradients. Magn Reson Med. 2006 Aug;56(2):235-9.</citation>
    <PMID>16929466</PMID>
  </reference>
  <reference>
    <citation>Cohen, A.D., et al. The effect of b-value on ADC values in a rat U87 brain tumor model. in 22nd Annual Meeting of the International Society of Magnetic Resonance in Medicine (ISMRM). 2014.Milan, Italy.</citation>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2017</study_first_submitted>
  <study_first_submitted_qc>September 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2017</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Jennifer Connelly</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Optune Therapy</keyword>
  <keyword>MRI</keyword>
  <keyword>NovoCure-TTF-200A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

